These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31272958)

  • 1. Treatment strategies for Graves' ophthalmopathy: a network meta-analysis.
    Zhou X; Zhou D; Wang J; Chen G
    Br J Ophthalmol; 2020 Apr; 104(4):551-556. PubMed ID: 31272958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous glucocorticoids therapy in the treatment of Graves' ophthalmopathy: a systematic review and Meta-analysis.
    Zhao LQ; Yu DY; Cheng JW
    Int J Ophthalmol; 2019; 12(7):1177-1186. PubMed ID: 31341811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common Immunosuppressive Monotherapy for Graves' Ophthalmopathy: A Meta-Analysis.
    Mou P; Jiang LH; Zhang Y; Li YZ; Lou H; Zeng CC; Wang QH; Cheng JW; Wei RL
    PLoS One; 2015; 10(10):e0139544. PubMed ID: 26469187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis.
    Li H; Yang L; Song Y; Zhao X; Sun C; Zhang L; Zhao H; Pan Y
    Acta Ophthalmol; 2022 Sep; 100(6):e1189-e1198. PubMed ID: 34918472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Gao G; Dai J; Qian Y; Ma F
    Clin Exp Ophthalmol; 2014 Nov; 42(8):769-77. PubMed ID: 24617953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis.
    Xu N; Cui Y; Xie T; Zheng M
    J Ophthalmol; 2018; 2018():7184163. PubMed ID: 30647961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts regarding Graves' orbitopathy.
    Bartalena L; Tanda ML
    J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
    Genere N; Stan MN
    Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis.
    Tu X; Dong Y; Zhang H; Su Q
    Biomed Res Int; 2018; 2018():4845894. PubMed ID: 30596092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
    Bello OM; Druce M; Ansari E
    BMJ Open Ophthalmol; 2024 Jun; 9(1):. PubMed ID: 38886120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy for Graves' ophthalmopathy: a systematic review and meta-analysis of randomized controlled trials.
    Viani GA; Boin AC; De Fendi LI; Fonseca EC; Stefano EJ; Paula JS
    Arq Bras Oftalmol; 2012 Oct; 75(5):324-32. PubMed ID: 23471326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
    Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
    Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
    Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves'ophthalmopathy: a systematic review and meta-analysis.
    Hu Y; Chen J; Lin K; Yu X
    Front Endocrinol (Lausanne); 2023; 14():1160936. PubMed ID: 37288301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
    Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
    Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
    Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves' orbitopathy: a meta-analysis.
    Feng W; Hu Y; Zhang C; Shi H; Zhang P; Yang Y; Chen S; Cui W; Cui D
    Bioengineered; 2022 Jun; 13(6):14719-14729. PubMed ID: 35959915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves' Ophthalmopathy to Parenteral Corticosteroids.
    Naselli A; Moretti D; Regalbuto C; Arpi ML; Lo Giudice F; Frasca F; Belfiore A; Le Moli R
    Front Endocrinol (Lausanne); 2020; 11():609895. PubMed ID: 33414766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.